Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01351610
Recruitment Status : Completed
First Posted : May 11, 2011
Last Update Posted : December 15, 2015
Information provided by (Responsible Party):
Apceth GmbH & Co. KG

Brief Summary:
MSC_Apceth are GMP-manufactured, autologous ex-vivo expanded non-hemapoietic bone-marrow derived stem cells for the treatment of Critical Limb Ischemia

Condition or disease Intervention/treatment Phase
Critical Limb Ischemia Peripheral Artery Disease Biological: PTA + Infusion of MSC_Apceth Procedure: PTA Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open, Randomized, Mono-Centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous Infusion of Human Bone Marrow Derived Autologous, CD34-Negative Mesenchymal Stem Cells for the Treatment of Critical Limb Ischemia in Patients With Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty
Study Start Date : March 2011
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group B Procedure: PTA
percutaneous transluminal angioplasty only

Experimental: Group A Biological: PTA + Infusion of MSC_Apceth
percutaneous transluminal angioplasty followed by infusion of MSC_Apceth

Primary Outcome Measures :
  1. Collection of adverse events [ Time Frame: one year ]
  2. Safety laboratory values [ Time Frame: 1 year ]
  3. ECG findings [ Time Frame: 1 year ]
  4. Analysis of inflammation markers [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Comparison of course of haemodynamic and vascular processes [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with peripheral arterial occlusive disease (symptomatic PAOD), diagnosis of CLI defined as persistent, recurring ischemic rest pain for at least 2 weeks, and/or ulceration or gangrene of the foot or toe, with an ABPI </= 0.5,
  2. Patients with staging of ≥III according to Fontaine and ≥4 according to Rutherford categories,
  3. Patients fulfilling the criteria for an invasive re-vascularisation procedure (PTA) at the discretion of the investigator,
  4. Patients without major amputation of the lower extremities within the period of 6 months after inclusion in the opinion of the investigator,

Exclusion Criteria:

  1. Patients with wounds of a severity of greater than grade 2 on the Wagner Scale,
  2. Patients with life-threatening ventricular arrhythmia,
  3. Patients with unstable angina pectoris,
  4. Patients with severe congestive heart failure (i.e. NYHA Stage IV),
  5. Patients with uncontrolled hypertension (defined as diastolic blood pressure >110 mmHg or systolic blood pressure >180 mmHg during screening),
  6. Patients with an uncontrolled diabetes mellitus (HbA1c > 9%),
  7. Patients having any history of malignant tumour in the anamnesis or are currently on tumour treatment,
  8. Patients who are unsuitable for a MSC stem cell therapy in the opinion of the investigator,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01351610

Layout table for location information
Isar Medizin Zentrum
Munich, Bavaria, Germany, 80331
Sponsors and Collaborators
Apceth GmbH & Co. KG
Layout table for investigator information
Principal Investigator: Peter Heider, MD, PhD Isar Medizin Zentrum, München
Layout table for additonal information
Responsible Party: Apceth GmbH & Co. KG Identifier: NCT01351610    
Other Study ID Numbers: MSC_Apceth_001
First Posted: May 11, 2011    Key Record Dates
Last Update Posted: December 15, 2015
Last Verified: December 2015
Keywords provided by Apceth GmbH & Co. KG:
Critical Limb Ischemia
Peripheral Arterial Occlusive Disease
Peripheral Artery Disease
Peripheral Vascular Disease
Stem Cell Therapy
Mesenchymal Stem Cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Chronic Limb-Threatening Ischemia
Arterial Occlusive Diseases
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Chronic Disease
Disease Attributes